{"filing":{"accession_number":"0001193125-26-347211","cik":"0001658678","ticker":"BSEM","company_name":"BioStem Technologies, Inc.","form":"8-K","filing_date":"2026-08-12","report_date":"2026-08-12","primary_document":"bsem-20260812.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1658678/000119312526347211/bsem-20260812.htm"},"events":[{"id":27373,"run_id":24941,"accession_number":"0001193125-26-347211","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"BioStem issued a press release on August 12, 2026 announcing financial results for Q2 2026 (three and six months ended June 30, 2026), disclosing net revenue of $7.9 million, gross profit of $4.8 million, and a GAAP net loss of $9.0 million per share. The filing explicitly states this is Item 2.02 (Results of Operations and Financial Condition) with the press release furnished as Exhibit 99.1, which is the standard format for earnings releases. The disclosure includes detailed financial statements, guidance updates, and operational metrics material to investor assessment.","company_name":"BioStem Technologies, Inc.","ticker":"BSEM","filing_date":"2026-08-12","form":"8-K","submitted_at":null,"items":[{"id":28882,"accession_number":"0001193125-26-347211","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"BioStem issued a press release on August 12, 2026 announcing financial results for Q2 2026 (three and six months ended June 30, 2026), disclosing net revenue of $7.9 million, gross profit of $4.8 million, and a GAAP net loss of $9.0 million per share. The filing explicitly states this is Item 2.02 (Results of Operations and Financial Condition) with the press release furnished as Exhibit 99.1, which is the standard format for earnings releases. The disclosure includes detailed financial statements, guidance updates, and operational metrics material to investor assessment.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T21:28:38.433750+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28882,"accession_number":"0001193125-26-347211","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"BioStem issued a press release on August 12, 2026 announcing financial results for Q2 2026 (three and six months ended June 30, 2026), disclosing net revenue of $7.9 million, gross profit of $4.8 million, and a GAAP net loss of $9.0 million per share. The filing explicitly states this is Item 2.02 (Results of Operations and Financial Condition) with the press release furnished as Exhibit 99.1, which is the standard format for earnings releases. The disclosure includes detailed financial statements, guidance updates, and operational metrics material to investor assessment.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T21:28:38.433750+00:00","company_name":"BioStem Technologies, Inc.","ticker":"BSEM","filing_date":"2026-08-12"}]}